Zydus Lifesciences
Zydus Lifesciences, formerly known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Founded in 1995, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Zydus Lifesciences focuses on research and development, manufacturing, and marketing of a diverse range of healthcare products, including generic medicines, biosimilars, and vaccines. With a commitment to innovation, Zydus Lifesciences has achieved significant milestones, such as the development of India's first indigenously produced DNA vaccine. The company is recognised for its robust portfolio of over 1,000 products, which cater to various therapeutic areas, making it a key player in the pharmaceutical market. Zydus Lifesciences continues to enhance its market position through strategic partnerships and a dedication to improving global health outcomes.
DitchCarbon Score
How does Zydus Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Lifesciences's score of 35 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zydus Lifesciences's reported carbon emissions
In 2023, Zydus Lifesciences reported total carbon emissions of approximately 307,414,000 kg CO2e, comprising 67,705,110 kg CO2e from Scope 1 and 239,708,530 kg CO2e from Scope 2 emissions. Additionally, the company recorded Scope 3 emissions of about 24,393,000 kg CO2e, which includes emissions from employee commuting and purchased goods and services. The previous year, 2022, saw total emissions of about 255,889,000 kg CO2e, with Scope 1 emissions at 59,573,850 kg CO2e and Scope 2 emissions at 191,170,970 kg CO2e, alongside Scope 3 emissions of 9,072,000 kg CO2e. This indicates a slight increase in total emissions from 2022 to 2023. Zydus Lifesciences has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they have reported emissions data across all three scopes, demonstrating a commitment to transparency in their environmental impact. The company continues to monitor and report its carbon footprint, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 2,409,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,039,000 | 0,000,000 | 00,000,000 | 0,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Lifesciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
